Evidence map›Paper›PMID 34830067›Full record

ArticleInternational journal of molecular sciences2021

IFN-Gamma and TNF-Alpha as a Priming Strategy to Enhance the Immunomodulatory Capacity of Secretomes from Menstrual Blood-Derived Stromal Cells.

María Ángeles de Pedro, María Gómez-Serrano, Federica Marinaro, Esther López, María Pulido, Christian Preußer, Elke Pogge von Strandmann, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Javier G Casado

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. TNF-Stem cells international · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

María Ángeles de PedroStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0002-8989-2468
María Gómez-SerranoInstitute for Tumor Immunology, Center for Tumor Biology and Immunology (ZTI), Philipps University, 35043 Marburg, Germany.ORCID 0000-0002-9669-091X
Federica MarinaroStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0001-5965-7718
Esther LópezStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0002-5051-5913
María PulidoStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0002-9126-7047
Christian PreußerInstitute for Tumor Immunology, Center for Tumor Biology and Immunology (ZTI), Philipps University, 35043 Marburg, Germany.ORCID 0000-0002-5183-4262
Elke Pogge von StrandmannInstitute for Tumor Immunology, Center for Tumor Biology and Immunology (ZTI), Philipps University, 35043 Marburg, Germany.
Francisco Miguel Sánchez-MargalloStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0003-2138-988X
Verónica ÁlvarezStem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.ORCID 0000-0002-7319-6089
Javier G CasadoCIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.ORCID 0000-0001-6797-7287
Centro de Cirugía de Mínima Invasión Jesús Usón · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ES

Funding

Banco Santander (Spain) Convenio de colaboración empresarial en actividades de interés generalCentro de Investigación en Red en Enfermedades Cardiovasculares CB16/11/00494Deutsche Forschungsgemeinschaft 416910386 - GRK 2573/1Government of Extremadura GR18199Government of Extremadura IB20184Instituto de Salud Carlos III CD19/00048Instituto de Salud Carlos III CP17/00021Instituto de Salud Carlos III FI19/00041Instituto de Salud Carlos III MS17/00021Instituto de Salud Carlos III PI18/0911
6 · The paper itself

Abstract

Mesenchymal stromal cells isolated from menstrual blood (MenSCs) exhibit a potent pro-angiogenic and immunomodulatory capacity. Their therapeutic effect is mediated by paracrine mediators released by their secretomes. In this work, we aimed to evaluate the effect of a specific priming condition on the phenotype and secretome content of MenSCs. Our results revealed that the optimal condition for priming MenSCs was the combination of interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) that produced a synergistic and additive effect on IDO1 release and immune-related molecule expression. The analyses of MenSC-derived secretomes after IFNγ and TNFα priming also revealed an increase in EV release and in the differentially expressed miRNAs involved in the immune response and inflammation. Proliferation assays on lymphocyte subsets demonstrated a decrease in CD4+ T cells and CD8+ T cells co-cultured with secretomes, especially in the lymphocytes co-cultured with secretomes from primed cells. Additionally, the expression of immune checkpoints (PD-1 and CTLA-4) was increased in the CD4+ T cells co-cultured with MenSC-derived secretomes. These findings demonstrate that the combination of IFNγ and TNFα represents an excellent priming strategy to enhance the immunomodulatory capacity of MenSCs. Moreover, the secretome derived from primed MenSCs may be postulated as a therapeutic option for the regulation of adverse inflammatory reactions.

Indexed as

AdultAntigens, SurfaceCoculture TechniquesExtracellular VesiclesFemaleGene Expression RegulationHealthy VolunteersHumansImmunomodulationIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaMenstruationMesenchymal Stem CellsMicroRNAsSecretomeT-LymphocytesAntigens, SurfaceIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaMicroRNAsTumor Necrosis Factor-alphaextracellular vesiclesmenstrual bloodmesenchymal stromal cellsprimingsecretome

Identifiers

PMID34830067
PMCPMC8618369
OpenAlexW3211557298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.